<DOC>
	<DOCNO>NCT02874092</DOCNO>
	<brief_summary>This open label study assess improvement Disease Activity Score 28-joint count ( DAS28 ) ticagrelor give 90 mg twice daily patient RA active disease despite MTX therapy ( define inclusion/exclusion criterion ) . There also cross sectional analysis baseline platelet activity subject rheumatoid arthritis osteoarthritis . Subjects OA cohort receive study medication , one study visit . Patients receive 90 mg ticagrelor orally bid . The patient receive drug 30-days . Methotrexate dose remain stable throughout study duration .</brief_summary>
	<brief_title>Ticagrelor Methotrexate-Resistant Rheumatoid Arthritis</brief_title>
	<detailed_description>The two main goal study demonstrate heighten cardiovascular risk RA compare platelet activity , inflammation endothelial function baseline rheumatoid arthritis versus age- sex-matched patient osteoarthritis ; 2 ) demonstrate effect ticagrelor rheumatoid arthritis pre- post- measure clinical RA severity , platelet activity , inflammation endothelial function rheumatoid arthritis ticagrelor therapy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Inclusion Criteria RA cohort Receiving MTX stable dos 10 25 mg weekly least 12 week Have DAS28 3.2 high ( The level disease activity consider low DAS28 3.2 less ) ( Prevoo et al. , 1995 ) OA cohort Diagnosis osteoarthritis make physician . RA cohort History sensitivity study medication excipients Previous intolerance MTX Current treatment antiplatelet therapy Absolute indication antiplatelet therapy Need chronic oral anticoagulant therapy Severe hepatic impairment ( eg , ascites and/or clinical sign coagulopathy ) Renal failure ( eGFR &lt; 30 require dialysis ) A know bleeding diathesis , hemostatic coagulation disorder , prior major bleed Prior stroke Active pathological bleeding History intracranial haemorrhage Life expectancy &lt; 12 month base investigator 's judgement Patients consider risk bradycardic event ( e.g. , know sick sinus syndrome second third degree atrioventricular [ AV ) ] block ) unless already treat permanent pacemaker Anemia ( hematocrit &lt; 27 % ) Platelet count &lt; 100,000/ml Concomitant use strong CYP 3A inhibitor inducer History thrombocytopenia neutropenia Pregnant nursing woman , female positive pregnancy test screening Females child bear potential use acceptable method birth control prior study Concern inability patient comply study procedure and/or follow ( eg , alcohol drug abuse ) OA cohort : History sensitivity study medication excipients Current treatment antiplatelet therapy Absolute indication antiplatelet therapy Need chronic oral anticoagulant therapy Severe hepatic impairment ( eg , ascites and/or clinical sign coagulopathy ) Renal failure ( eGFR &lt; 30 require dialysis ) A know bleeding diathesis , hemostatic coagulation disorder , prior major bleed Prior stroke Active pathological bleeding History intracranial haemorrhage Life expectancy &lt; 12 month base investigator 's judgement Anemia ( hematocrit &lt; 27 % ) Platelet count &lt; 100,000/ml History thrombocytopenia neutropenia Pregnant nursing woman , female positive pregnancy test screening Females child bear potential use acceptable method birth control prior study Concern inability patient comply study procedure and/or follow ( eg , alcohol drug abuse )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Methotrexate ( MTX )</keyword>
	<keyword>Ticagrelor</keyword>
</DOC>